The Evaluation of New Antiarrhythmic Drugs

Proceedings of the Symposium on How to Evaluate a New Antiarrhythmic Drug: The Evaluation of New Antiarrhythmic Agents for the Treatment of Ventricular Arrhythmias, held at Philadelphia, Pennsylvania, October 8–9, 1980

  • Joel Morganroth
  • E. Neil Moore
  • Leonard S. Dreifus
  • Eric L. Michelson

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 11)

Table of contents

  1. Front Matter
    Pages I-XIV
  2. How to Evaluate a new Antiarrhythmic Drug: The Challenge of Sudden Cardiac Death

  3. Pre-Clinical Evaluation of a New Antiarrhythmic Agent

  4. Chronic Studies in Patients with Non-Hemodynamically Significant Ventricular Arrhythmics

  5. Study Designs: Chronic Patients

    1. D. M. Krikler
      Pages 137-138
    2. Joel Morganroth, E. Neil Moore, Leonard S. Dreifus, Eric L. Michelson
      Pages 159-178
  6. Acute Studies in Patients with Hemodynamically Significant Significant Ventricular Arrhythmias

  7. Special Considerations

    1. R. S. Aronson, S. Siskind, E. H. Sonnenblick
      Pages 247-270

About this book

Introduction

Thus, there are now several chronic canine myocardial infarction­ ventricular tachyarrhythmia models which are available for the evaluation of new antiarrhythmic drugs (Table I). The available models fulfill many, but not all of the requirements for an ideal chronic arrhythmia model (Table 11). The sustained arrhythmias initiated in these models using programmed pacing presumably have the same localized reentrant mechanism that characterizes chronic human myocardial infarction and chronic coronary 26 artery disease. However, these models are not suitable for determining whether a new drug will abolish spontaneous ly-occurring PVCs. In addition, these models are of unproven value in the study of acute spontaneously­ occurring sudden death; although recently initiated, provocative work may shed further light on this subject. Most importantly, the available models do seem well-suited to the evaluation of new drugs intended for use in chronic coronary artery disease patients at risk for sustained reentrant ventricular tachycardia or VF. Notably, the results of preliminary electropharmacologic studies in these canine models parallel closely those findings reported in human patients with sustained life-threatening ventricu­ lar tachyarrhythmias (Table Ill). Therefore, increased use of these chronic models for new antiarrhythmic drug testing is strongly recommended. TABLE II Ideal vs Available Chronic Canine - Arrhythmia Models Ideal Available 1. (a) Arrhythmia mechanism comparable to Yes patients with chronic CAD: Reentry (b) Pathophysiology similar (e. g. , atherogenic CAD) No 2. Susceptible to: (a) spontaneous PVCs No l No (b) spontaneous VT/VF (c) inducible VT/VF Yes 3.

Keywords

arrhythmia drugs electrophysiology myocardial infarction pharmacodynamics physiology sudden cardiac death

Editors and affiliations

  • Joel Morganroth
    • 1
  • E. Neil Moore
    • 2
  • Leonard S. Dreifus
    • 1
  • Eric L. Michelson
    • 1
  1. 1.The Lankenau HospitalPhiladelphiaUSA
  2. 2.School of Veterinary MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-8270-3
  • Copyright Information Springer Science+Business Media B.V. 1981
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-009-8272-7
  • Online ISBN 978-94-009-8270-3
  • Series Print ISSN 0166-9842
  • About this book